XML 30 R14.htm IDEA: XBRL DOCUMENT v3.7.0.1
Intangible assets
 12 Months Ended
Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Disclosure [Text Block]
8.
Intangible assets:
 
 
 
 
 
Accumulated
 
Net book
 
2016
 
Cost
 
amortization
 
value
 
 
 
 
 
 
 
 
 
Licenses
 
$
12,843
 
$
856
 
$
11,987
 
Marketing rights
 
 
15,830
 
 
4,948
 
 
10,882
 
Trade name
 
 
1,131
 
 
353
 
 
778
 
Patents
 
 
4,347
 
 
3,642
 
 
705
 
 
 
 
 
 
 
 
 
 
 
 
 
 
$
34,151
 
$
9,799
 
$
24,352
 
 
 
 
 
 
Accumulated
 
Net book
 
2015
 
Cost
 
amortization
 
value
 
 
 
 
 
 
 
 
 
Marketing rights
 
$
15,830
 
$
3,365
 
$
12,465
 
Trade name
 
 
1,131
 
 
240
 
 
891
 
Patents
 
 
4,312
 
 
3,447
 
 
865
 
 
 
$
21,273
 
$
7,052
 
$
14,221
 
 
In the second quarter of 2016, the Company announced the execution of a license agreement with Allergan plc (“Allergan”), for the rights to commercialize dalbavancin (branded DALVANCE® in the U.S. and XYDALBATM in the rest of the world) in France, the United Kingdom, Germany, Belgium, Nordic nations, other European nations, various Middle Eastern nations, and Canada. As consideration for the rights and licenses granted, the Company made non-refundable payments to Allergan of $13,000, along with incurring other transaction costs. Additional non-refundable milestone payments will be due to Allergan upon the Company’s achievement of various milestones. Royalty payments may also be due to Allergan based on achievement of pre-determined levels of annual net sales. The license will be amortized over the life of the agreement of 10 years.
 
Amortization expense for the year ended December 31, 2016 amounted to $2,783 (2015 - $1,974).
 
The estimated aggregate amortization expense for intangible assets held at December 31, 2016, for each of the five succeeding years is expected as follows:
 
2017
 
$
3,158
 
2018
 
 
3,126
 
2019
 
 
3,104
 
2020
 
 
3,083
 
2021
 
 
3,048